Established cancer drug can reactivate immunotherapy

Established cancer drug can reactivate immunotherapy

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune cells recognize gradually vanish. Researchers at the Technical University of Munich (TUM) have now identified one of the molecular mechanisms behind this process. In an initial study, they succeeded in blocking it using an existing cancer drug.